Du är här

2016-01-25

Medigene AG: Medigene and the University of Lausanne agree on collaboration to explore new technologies for the characterisation of Medigene's T cell receptors

Medigene AG / Medigene and the University of Lausanne agree on collaboration
to explore newtechnologies for the characterisation of Medigene's T cell
receptors (TCRs) . Processed and transmitted by NASDAQ OMX Corporate
Solutions.The issuer is solely responsible for the content of this
announcement.
Martinsried/Munich, 25 January 2016.
Medigene AG(MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology
company focusing on the development of T cell immune-therapies for the
treatment of cancer, announces a collaboration agreement with the University
of Lausanne, Switzerland in order to establish a better and faster method for
selecting tumour-specific T cells characterised by expression of suitable T
cell receptors (TCRs) for Medigene's expanding TCR library. The agreement
provides Medigene access to the state-of-the-art NTAmer technology that has
been established by TCMetrix, a spin-off company of the Ludwig Institute for
Cancer Research in Lausanne, and further developed in collaboration with
leading scientists of the University of Lausanne. Financial terms of the
agreement were not disclosed.

Prof. Dr. Dolores Schendel, CSO and designated CEO of Medigene, comments:
"With this cooperation we are able to explore a cutting-edge technology in
order to complement our comprehensive TCR platform. The NTAmer technology
supports us to gain additional information about the structural avidity[1]of
TCRs by using direct assessment of living T cells. This will help us to
select TCRs with optimal target antigen sensitivity for inclusion in our TCR
library that is developed in order to treat patients with different MHC
backgrounds and various types of cancer."

Prof. Dr. George Coukos, Professor at the University of Lausanne and Director
of the Ludwig Institute for Cancer Research in Lausanne, added:
"The development of personalised, cell-based immunotherapies is a major
objective of Ludwig Lausanne, as such approaches hold great promise for the
treatment of cancers. We are very pleased to be working with Medigene to help
advance its innovative TCR technology and are hopeful that it will ultimately
be of significant benefit to cancer patients, especially those with advanced
and refractory disease."

Within the framework of the cooperation, scientists of the Department of
Oncology of the University of Lausanne will perform kinetic dissociation
analyses on human T cells (T cells expressing Medigene's proprietary TCR
candidates) using the innovative NTAmer technology. This technology measures
cell-surface monomeric TCR-peptide-MHC dissociation rates (the so-called TCR
structural avidity) of TCR candidates, which will allow Medigene to select
tumour-specific T cells with an optimal functional avidity for different
cancer cell types. The tailor-made NTAmer reagents are patented and will be
provided by TCMetrix Ltd.

About Medigene's TCR technology:
Medigene's technology for T cell receptor modified T cells is one of the
Company's highly innovative and complementary immunotherapy platforms for
adoptive T cell therapy. The TCR therapy is designed to treat patients with
high tumour loads. The clinical development of Medigene's TCRs is in
preparation.

The TCR technology aims to arm the patient's own T cells with tumour-specific
T cell receptors. The receptor-modified T cells are then able to detect and
efficiently kill tumour cells. This form of immunotherapy aims to overcome
the patient's tolerance to cancer cells and tumour-induced immunosuppression,
by activating and modifying the patient's T cells outside the body (ex vivo).
A large number of specific T cells to fight the tumour is made available to
patients within a short period of time.

In the context of this platform Medigene is developing a comprehensive library
of recombinant T cell receptors. Moreover, a good manufacturing practice
(GMP)-compliant process for their combination with patient-derived T cells is
currently being established.

Medigene is preparing the clinical development of the first product
candidates. In addition, novel TCRs with specificities for promising
tumour-associated antigens will be isolated and further characterised. In the
coming years, Medigene plans to develop up to 10 lead candidates for the TCR
technology in the next years and aims to initiate up to three clinical TCR
trials, the first to be started in 2016 (IIT phase I study with participation
of Medigene, subject to grant funding). Medigene-sponsored trials are planned
to start in the second half of 2017 and in the second half of 2018.

Further audio-visual education about Medigene's TCR technology
at:https://vimeo.com/123007480

Medigene AG
is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company
headquartered in Martinsried near Munich, Germany. The company is developing
highly innovative, complementary treatment platforms to target various types
and stages of cancer with candidates in clinical and pre-clinical
development. Medigene concentrates on the development of personalized T
cell-based immunotherapies.

For more information, please visitwww.medigene.com

This press release contains forward-looking statements representing the
opinion of Medigene as of the date of this release. The actual results
achieved by Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of these
forward-looking statements. Medigene®is a registered trademark of Medigene
AG. This trademark may be owned or licensed in select locations only.

Contact Medigene

Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please
inform us by e-mail (investor@medigene.com). We will then delete your address
from our distribution list.
---------------------------------------[1]Avidity is commonly applied to antibody interactions in which multiple
antigen-binding sites simultaneously interact with the target antigenic
epitopes, often in multimerised structures.

Press release English PDF
http://hugin.info/132073/R/1980731/725692.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire

HUG#1980731

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.